Re: Assessment of elimination half life of mAb

> On Apr 29, 2021, at 11:34 AM, Niurys.CS <[email protected]> wrote: > > Dear all, > > I'm very grateful for these ideas and explanations. Actually, I was worry > about this topic. Previously, I reported the values of half life by NCA; > however the clinicians are asking for a half life value estimated by > population PK. > Many thanks to you in the name of Cuban team. > Niurys > > El 29/04/2021 12:49, "Bonate, Peter" <[email protected]> escribió: > All I can say is, Great minds..... > > Maybe some of these ideas can help you, Niurys. > > pete > > > > Peter Bonate, PhD > Executive Director > Pharmacokinetics, Modeling, and Simulation (PKMS) > Clinical Pharmacology and Exploratory Development (CPED) > Astellas > 1 Astellas Way, N3.158 > Northbrook, IL 60062 > [email protected] > (224) 619-4901 > > > It’s been a while since I’ve had something here, but here is a Dad joke. > > Question: Do you know why the math book was sad? > Answer: Because it had so many problems > > > -----Original Message----- > From: Leonid Gibiansky <[email protected]> > Sent: Thursday, April 29, 2021 11:42 AM > To: Justin Wilkins <[email protected]>; Bill Denney > <[email protected]>; Bonate, Peter <[email protected]>; > Niurys.CS <[email protected]> > Cc: [email protected] > Subject: Re: [NMusers] Assessment of elimination half life of mAb > > still, half-life of the linear part could be helpful in cases when > non-linearity plays no significant role in elimination, so we tend to present > it together with the washout time simulations. > > Leonid > > > > On 4/29/2021 12:35 PM, Justin Wilkins wrote: > > Hi Bill, all, > > > > I do much the same thing - when there's nonlinearity happening, I've found > > it to be effective to plot concentration-time curves by doses and regimens > > of interest and mark the times at which the (median?) clinically-defined > > threshold for "washout" has been reached in each case. Of course this > > starts getting unwieldy when there are lots of doses or regimens. A less > > attractive way would be to produce a lookup table. > > > > Sounds like everyone's thinking along the same lines... > > > > Justin > > > > > > -----Original Message----- > > From: [email protected] <[email protected]> On > > Behalf Of Bill Denney > > Sent: Thursday, April 29, 2021 6:17 PM > > To: Bonate, Peter <[email protected]>; Leonid Gibiansky > > <[email protected]>; Niurys.CS <[email protected]> > > Cc: [email protected] > > Subject: RE: [NMusers] Assessment of elimination half life of mAb > > > > Hi Pete, > > > > I agree that it is hard to communicate. I like the general idea of C90 you > > propose. I tend to choose something in between your and Leonid's answer, > > when possible. I target an answer of "when is the pharmacodynamic effect > > <5% of the maximum or therapeutic effect". It does require more than just > > the PK, though. And for the just PK answer, I agree with Leonid and you, > > targeting some smallish fraction of Cmax is often reasonable for similar > > communication. > > > > What I find clinicians typically try to understand when the drug has washed > > out. The answer that many have reasonably latched onto is when 5 > > half-lives have passed, the drug is washed out. That suggests that about > > 3% (2^-5) effect is generally agreed as being washed out. > > > > To Niurys's question about a citation for this, I don't have one either. > > It's just a rule-of-thumb that I have tended to use. > > > > Thanks, > > > > Bill > > > > -----Original Message----- > > From: [email protected] <[email protected]> On > > Behalf Of Bonate, Peter > > Sent: Thursday, April 29, 2021 12:01 PM > > To: Leonid Gibiansky <[email protected]>; Niurys.CS > > <[email protected]> > > Cc: [email protected] > > Subject: RE: [NMusers] Assessment of elimination half life of mAb > > > > I've never really been happy with this. It's an unsatisfactory solution. > > You have a nonlinear drug. Let's assume you have an approved drug. It's > > given at some fixed dose. The clinician wants to know what is the drug's > > half-life so they can washout their patient and start them on some other > > therapy. We go back to them and say, we can't give you a half-life because > > it's a nonlinear drug, but once the kinetics become linear the half-life is > > X hours. That is a terrible answer. Maybe we need to come up with a new > > term, call it C90, the time it takes for Cmax to decline by 90%. That we > > can do. We don't even need an analytical solution, we can eyeball it. We > > could even get fancy and do it in a population model. C90 - the time it > > takes for Cmax to decline 90% in 90% of patients. Of course, for nonlinear > > drugs, C90 only holds for that dose. Change in dose results in a new C90. > > Just a thought. > > > > pete > > > > > > > > Peter Bonate, PhD > > Executive Director > > Pharmacokinetics, Modeling, and Simulation (PKMS) Clinical > > Pharmacology and Exploratory Development (CPED) Astellas > > 1 Astellas Way, N3.158 > > Northbrook, IL 60062 > > [email protected] > > (224) 619-4901 > > > > > > It’s been a while since I’ve had something here, but here is a Dad joke. > > > > Question: Do you know why the math book was sad? > > Answer: Because it had so many problems > > > > > > -----Original Message----- > > From: [email protected] <[email protected]> On > > Behalf Of Leonid Gibiansky > > Sent: Thursday, April 29, 2021 9:54 AM > > To: Niurys.CS <[email protected]> > > Cc: [email protected] > > Subject: Re: [NMusers] Assessment of elimination half life of mAb > > > > I am not aware of any papers specifically addressing the half-live > > issue, but there are tons of original papers and tutorials on TMDD, > > just search the web Thanks Leonid > > > > On 4/29/2021 9:48 AM, Niurys.CS wrote: > >> Dear Leonid, > >> > >> Many thanks for clearing up my doubt. Can you suggest me any paper to > >> go into this topic in any depth. > >> Best, > >> Niurys > >> > >> El 28/04/2021 19:34, "Leonid Gibiansky" <[email protected] > >> <mailto:[email protected]>> escribió: > >> > >> There is no such thing as half-life of elimination for the nonlinear > >> drug. But one can compute something like half-life: > >> > >> 1. Half-life of the linear part (defined by CL, V1, V2, Q): this > >> defines the half-life at high doses/high concentrations when > >> nonlinear elimination is saturated. > >> > >> 2. Washout time: for the linear drug, 5 half-lives can be used to > >> define washout time. During this time, concentrations drop > >> approximately 2^5=32 times. So one can simulate the desired dosing > >> (single dose or steady state), find the time from Cmax to Cmax/32 > >> and call it washout time (or time to Cmax/64 to be conservative) > >> > >> Thanks > >> Leonid > >> > >> > >> On 4/28/2021 5:17 PM, Niurys.CS wrote: > >> > >> Dear all > >> I need some help to assess the elimination half life of a > >> monoclonal antibody. > >> The model that describes the data is a QSS aproximation of TMDD > >> with Rmax constant. The model includes two binding process of > >> mAb to its target: in central and peripheral compartments. > >> Is there any specific equation to calcule lambda z and the > >> elimination half life for each of the TMDD aproximations? > >> Thanks > >> Niurys > >> > >